- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05223179
Intramuscular CodaVax-H1N1 in Healthy Adults
Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability, and Immunogenicity of Intramuscular CodaVax-H1N1 in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years. Participants will be enrolled in autumn 2022 (southern hemisphere) and followed through the 2022 influenza season (Part A) or enrolled in autumn 2023 and followed through the 2023 influenza season. Participants will be screened within 28 days of randomization, and eligible participants in Part A will be enrolled into 1 of 3 sequential cohorts and randomised to receive a single dose of CodaVax-H1N1, placebo (normal saline), or licensed injectable seasonal influenza vaccine (Flucelvax Quad). Each subsequent cohort will include a higher dose of CodaVax H1N1 than the previous cohort, in addition to placebo and the licensed injectable seasonal influenza vaccine. In Part B, 24 eligible participants will be enrolled into 1 of 2 additional sequential cohorts and randomised to receive a single IM dose of CodaVax-H1N1 or placebo.
Participants will record reactogenicity events (local events, systemic events, and temperature) in a daily diary for 7 days after the dose. Each participant will be contacted by telephone on the day after dosing for safety assessment and review of the diary data. Participants will return to the clinic on Days 4, 8, 29, 91, and 181 for safety and immune response assessments.
All adverse events and concomitant medications will be recorded from signing of the informed consent form (ICF) to 28 days postdose. After 28 days until the end of the study, only medically attended adverse events (MAAEs), new onset chronic illnesses (NCIs), serious adverse events (SAEs), immunosuppressive medications, blood products like transfusions or infusions, and vaccines will be recorded. A complete physical examination will be performed at Screening, and targeted and symptom-driven physical examinations will be performed predose on Day 1, 2 hours postdose, and at each postdose visit through Day 91. Vital signs will be measured at the same time points. An electrocardiogram (ECG) will be performed at Screening and on Day 29.
A serum sample will be collected predose and on Days 29, 91, and 181 for measurement of immune response.
A whole blood sample will be collected predose and on Day 8 and PBMCs isolated for measurement of T-cell response.
If a participant experiences acute symptoms compatible with viral respiratory infection, nasopharyngeal swab samples will be collected for a rapid influenza diagnostic test and respiratory virus PCR assay panel (including SARS-CoV-2) as indicated for symptomatic respiratory infection and will perform the rapid influenza diagnostic test.
The primary analysis of study data will be conducted after all participants complete the Day 29 visit. The final analysis will be conducted at the end of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Lis Gilmour, Senior Project Manager
- Phone Number: +61 7 5456 3986
- Email: CTCParticipantRecruitment@usc.edu.au
Study Locations
-
-
Queensland
-
Morayfield, Queensland, Australia, QLD 4556
- Lis Gilmour, Senior Project Manager
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2
- In good health with no history, or current evidence, of clinically significant medical conditions
- Negative SARS-CoV-2 test predose on Day 1
- For all women, negative pregnancy test
- Agreement to comply with conditions to prevent the spread of genetically modified organisms (GMOs)
Exclusion Criteria:
- Pregnant or lactating women or women who plan to become pregnant through Day 29
- Inadequate venous access for repeated phlebotomy
- History of severe reaction to vaccination
- Receipt of any licenced or investigational influenza vaccine within 6 months before Day 1
- Receipt of any live vaccine within 30 days before Day 1
- Tattoo, skin reaction, or other condition at the injection site that would interfere with assessment of local reactogenicity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CODA-VAX H1N1
Live Attenuated Vaccine administered by Intramuscular Injection
|
Intramuscular Live Attenuated Influenza H1N1 Vaccine
|
Active Comparator: Flucelvax Quad
Licensed Injectable Seasonal Influenza Vaccine
|
Licensed Seasonal Injectable Influenza Vaccine
|
Placebo Comparator: Saline
Normal Sterile Saline for Intramuscular Injection
|
Saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability by Assessing Percentage of Participants with Reactogenicity Events
Time Frame: Reactogenicity events from Day 1 to Day 7
|
Percentage of participants with reactogenicity events
|
Reactogenicity events from Day 1 to Day 7
|
Safety and Tolerability by Assessing Percentage of Participants with Adverse Events
Time Frame: Adverse events (AEs) from Day 1 to Day 29
|
Percentage of participants with adverse events
|
Adverse events (AEs) from Day 1 to Day 29
|
Safety and Tolerability by Assessing Percentage of Participants with MAAEs, NCIs, and SAEs.
Time Frame: MAAEs, NCIs, SAEs from Day 1 to Day 181
|
Percentage of participants with MAAEs, NCIs, and SAEs.
|
MAAEs, NCIs, SAEs from Day 1 to Day 181
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral Immunogenicity
Time Frame: HAI assay titre against A/California/07/2009 and the current seasonal influenza vaccine H1N1 and H3N2 strains measured in samples collected on Days 1, 29, 91, and 181
|
To assess the humoral immunogenicity elicited by CodaVax-H1N1 at nominal doses of 5×104, 5×105, and 5×106 PFU by IM injection
|
HAI assay titre against A/California/07/2009 and the current seasonal influenza vaccine H1N1 and H3N2 strains measured in samples collected on Days 1, 29, 91, and 181
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDX-FLU-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza, Human
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
AVIR Green Hills Biotechnology AGCompletedSeasonal Human InfluenzaAustria
-
Emergent BioSolutionsCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Hualan Biological Engineering, Inc.Completed
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Research Institute for Biological Safety ProblemsResearch Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...Completed
-
Novartis VaccinesCompleted
Clinical Trials on CODA-VAX H1N1
-
University of MichiganRecruiting
-
Chonnam National University HospitalUnknownMultiple MyelomaKorea, Republic of
-
University of OxfordCancer Institute and Hospital, Chinese Academy of Medical Sciences; Qidong... and other collaboratorsCompletedLiver Diseases | Hepatitis B | Liver NeoplasmsUnited Kingdom, China
-
University of PennsylvaniaPhiladelphia Department of Public HealthCompleted
-
Entos Pharmaceuticals Inc.Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma... and other collaboratorsCompletedSARS-CoV-2Burkina Faso, Canada, Senegal, South Africa
-
Baiya Phytopharm Co., Ltd.National Vaccine Institute, ThailandActive, not recruiting
-
Uppsala UniversityKarolinska Institutet; Cyto Pulse Sciences, Inc.Completed
-
Instituto Nacional de Salud Publica, MexicoLaboratorios de Biologicos y Reactivos de México, S.A. de C.V.Withdrawn
-
Vaxcyte, Inc.Active, not recruitingPneumococcal VaccinesUnited States
-
Dr. Nechama SharonUnknown